No connection

Search Results

Analysis Neutral

With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug

Mar 31, 2026 14:45 UTC

The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker..

Share this article

Related Articles

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Home
Terminal
AI
Markets
Profile